ESTRO 2025 - Abstract Book

S1858

Clinical – Upper GI

ESTRO 2025

disease following chemotherapy achieved a significantly higher median OS compared to patients with progressive extrapancreatic metastatic disease (14 months vs. 5 months, p=0.01). Chemotherapy was resumed in 83% of patients following MRgRT, with median chemotherapy-free interval of 3 months. Treatment-related toxicities were manageable, with no acute grade ≥3 events and two late grade 3 events (9%). No grade 4 or 5 events occured. Conclusion: Five-fraction MRgRT demonstrates favorable outcomes in mPDAC patients , with an acceptable safety profile, particularly in those with controlled single-organ extrapancreatic site following upfront chemotherapy. These findings support further research to optimize patient selection.